





**Figure 1. Median percent reductions in POS and SGS frequency per 28 days from baseline to Weeks 1–13 and 40–52 by (A) number of concomitant baseline ASMs and (B) the most common concomitant baseline ASMs (Full Analysis Set; Japanese patients)**

**A Number of concomitant baseline ASMs**



**B Most common concomitant baseline ASMs**



ASM, anti-seizure medication; POS, partial-onset seizures; SGS, secondarily generalized seizures